BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.12 -1.42%
Revenue Growth %: +13.2%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +13.2%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.46, $0.31 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $875 million versus the consensus estimate of $829.31 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.95-$5.15, versus the consensus of $5.33. BioMarin Pharma sees FY2026 revenue of $3.325-3.425 billion, versus the consensus of $3.378 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Occidental Petroleum releases Q2 2026 earnings considerations
- Niagen Bioscience files to sell up to $50M in common stock
- Holtec Nuclear Corporation files for initial public offering
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
